A 37-year-old man with obesity, type 2 diabetes and chronic kidney disease presented with multiple embolic strokes while taking rivaroxaban for recurrent unprovoked deep vein thrombosis. Transoesophageal echocardiography revealed a sessile aortic valve mass. Repeated blood cultures and 18F-FDG PET-CT returned negative results, and lupus anticoagulant was the only antiphospholipid antibody detected; the study team described this as probable antiphospholipid syndrome (APS). The treating clinicians stopped rivaroxaban, initiated low-molecular-weight heparin and acenocoumarol, and pursued surgical excision of the mass. Histology identified an organised fibrinous thrombotic vegetation, though the authors noted papillary fibroelastoma could not be fully excluded.
The case reads as an example of embolic events occurring despite oral factor Xa inhibition. The authors reported the clinical sequence and imaging-pathology correlation, and they documented anticoagulant change and operative management as the immediate response to suspected non-bacterial thrombotic valvular disease in APS.
Following CABARET recommendations for case-based reviews, the investigators searched MEDLINE/PubMed, Scopus, Web of Science and DOAJ for reports published between January 2020 and September 2026. Their selection produced 62 case reports/series accounting for 63 patients, plus four cohort studies; the manuscript synthesised these observational data without hypothesis testing.
Demographics and APS classification varied between reports. Median age across patients was 40 years (range 19–78). Sex distribution (when reported) showed 22/60 patients (37%) were men. Primary APS was reported in 34/63 patients (54%) and catastrophic APS in 6/63 (10%). When antibody panels were provided, 22/39 patients (56%) were described as triple-positive, while lupus-anticoagulant-only status was recorded in 4/39 (10%). The authors documented these numbers as extracted from the published reports; they did not provide pooled inferential statistics beyond descriptive counts.
Valve involvement was heterogeneous. Across the 62 reports that recorded valve location, the mitral valve was affected in 41/62 cases (66%), the aortic valve in 19/62 (31%) and the tricuspid valve in 7/62 (11%). Clinical consequences were substantial: ischaemic stroke occurred in 29/63 patients (46%) and heart failure or severe valve dysfunction was present in 31/63 (49%).
The authors also reported management outcomes: of 16 patients who were anticoagulated at diagnosis, 10 (63%) were receiving a DOAC. Valve intervention — repair or replacement — was performed in 35/63 patients (56%), and mortality across the compiled reports was 4/63 (6%). These counts came directly from the case reports and cohorts the authors included in their review.
The index patient’s presentation prompted a switch from rivaroxaban to low-molecular-weight heparin and acenocoumarol. Across the reviewed literature the authors emphasised that several patients experienced embolic events while on DOACs, a finding that emerged from case descriptions rather than controlled comparison. The report did not provide randomized or prospective trial data comparing direct oral anticoagulants with vitamin K antagonists in Libman-Sacks endocarditis; the authors relied on observational reports and cohort descriptions for therapeutic signals.
Where histology was available, organised thrombotic vegetations were reported. The investigators documented use of surgical excision and valve intervention in more than half of patients, reflecting both embolic risk and valve dysfunction as drivers for operative management. The review did not specify standardized anticoagulation dosing regimens or duration across cases; those granular treatment details were not uniformly reported in the source material.
The authors clearly stated the evidence base is observational and derived mainly from case reports, small series and a limited number of cohort studies. They reported counts and clinical descriptors but did not present pooled effect estimates or controlled comparisons. Important methodological limitations included inconsistent antibody-panel reporting, variable imaging and histologic confirmation across cases, and sparse detail on anticoagulant dosing and monitoring in many reports.
Key unanswered questions that remain in the published record include whether DOACs confer higher risk of breakthrough arterial embolism in APS-related Libman-Sacks endocarditis compared with vitamin K antagonists, which patient subgroups (for example, triple-positive antibody profiles) are at greatest risk, and what standardized criteria should prompt surgical intervention. The authors recommended clinicians consider LSE in APS patients with embolic events, particularly when events occur on DOACs, but they emphasised that robust comparative data are lacking and that evidence remains observational.
The review ends with the practical, research-oriented caveat that high-quality prospective data are needed to inform anticoagulant choice and timing of valve intervention in APS-associated non-bacterial thrombotic endocarditis. The source did not report randomized trial results, nor did it provide detailed, uniform anticoagulation regimens across included cases.